ClinicalTrials.Veeva

Menu

Glin4: Assessment of the Glycemic Responses to Nutritional Products (GLIN4)

Nutricia logo

Nutricia

Status and phase

Completed
Phase 4

Conditions

Glycemic Response

Treatments

Dietary Supplement: First Concept product
Dietary Supplement: Seventh Concept product
Dietary Supplement: Second Concept product
Dietary Supplement: Second reference product
Dietary Supplement: Third reference product
Dietary Supplement: First Reference product
Dietary Supplement: Sixth Concept product
Dietary Supplement: Fifth Concept product
Dietary Supplement: Fourth Concept product
Dietary Supplement: Third Concept product

Study type

Interventional

Funder types

Industry

Identifiers

NCT06797349
24REX0080350

Details and patient eligibility

About

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

Enrollment

12 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 and ≤ 65 years
  2. Body mass index (BMI) between 18.5 and 27 kg/m²

Exclusion criteria

  1. Baseline fasting Glucose ≥6.1 at screening visit
  2. Known history of gastrointestinal disease, bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2)affect the results.
  3. Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
  4. Major trauma or surgical event within 3 months of screening.
  5. Known intolerance, sensitivity or allergy to test products.
  6. Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
  7. History of cancer in the prior two years, except for non-melanoma skin cancer.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

12 participants in 10 patient groups

Arm 1
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: First Reference product
Arm 2
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: Second reference product
Arm 3
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: Third reference product
Arm 4
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: First Concept product
Arm 5
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: Second Concept product
Arm 6
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: Third Concept product
Arm 7
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: Fourth Concept product
Arm 8
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: Fifth Concept product
Arm 9
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: Sixth Concept product
Arm 10
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: Seventh Concept product

Trial contacts and locations

1

Loading...

Central trial contact

Danone Nutricia Research

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems